<?xml version='1.0' encoding='utf-8'?>
<document id="27756789"><sentence text="Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants."><entity charOffset="57-66" id="DDI-PubMed.27756789.s1.e0" text="Tamoxifen" /></sentence><sentence text="Tamoxifen is an estrogen receptor antagonist used in the treatment of breast cancer"><entity charOffset="0-9" id="DDI-PubMed.27756789.s2.e0" text="Tamoxifen" /><entity charOffset="16-24" id="DDI-PubMed.27756789.s2.e1" text="estrogen" /><pair ddi="false" e1="DDI-PubMed.27756789.s2.e0" e2="DDI-PubMed.27756789.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27756789.s2.e0" e2="DDI-PubMed.27756789.s2.e1" /></sentence><sentence text=" It is a prodrug that is converted by several cytochrome P450 enzymes to a primary metabolite, N-desmethyltamoxifen (NDT), which is then further modified by CYP2D6 to a pharmacologically potent secondary metabolite, 4-hydroxy-N-desmethyltamoxifen (endoxifen)"><entity charOffset="95-115" id="DDI-PubMed.27756789.s3.e0" text="N-desmethyltamoxifen" /><entity charOffset="117-120" id="DDI-PubMed.27756789.s3.e1" text="NDT" /><entity charOffset="216-246" id="DDI-PubMed.27756789.s3.e2" text="4-hydroxy-N-desmethyltamoxifen" /><entity charOffset="248-257" id="DDI-PubMed.27756789.s3.e3" text="endoxifen" /><pair ddi="false" e1="DDI-PubMed.27756789.s3.e0" e2="DDI-PubMed.27756789.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27756789.s3.e0" e2="DDI-PubMed.27756789.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27756789.s3.e0" e2="DDI-PubMed.27756789.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27756789.s3.e0" e2="DDI-PubMed.27756789.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27756789.s3.e1" e2="DDI-PubMed.27756789.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27756789.s3.e1" e2="DDI-PubMed.27756789.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27756789.s3.e1" e2="DDI-PubMed.27756789.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27756789.s3.e2" e2="DDI-PubMed.27756789.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27756789.s3.e2" e2="DDI-PubMed.27756789.s3.e3" /></sentence><sentence text=" Antidepressants (ADs), which are often coprescribed to patients receiving tamoxifen, are also metabolized by CYP2D6 and evidence suggests that a drug-drug interaction between these agents adversely affects the outcome of tamoxifen therapy by inhibiting endoxifen formation"><entity charOffset="75-84" id="DDI-PubMed.27756789.s4.e0" text="tamoxifen" /><entity charOffset="222-231" id="DDI-PubMed.27756789.s4.e1" text="tamoxifen" /><pair ddi="false" e1="DDI-PubMed.27756789.s4.e0" e2="DDI-PubMed.27756789.s4.e0" /><pair ddi="true" e1="DDI-PubMed.27756789.s4.e0" e2="DDI-PubMed.27756789.s4.e1" /></sentence><sentence text=" We evaluated this potentially important drug-drug interaction in vivo in mice humanized for CYP2D6 (hCYP2D6)" /><sentence text=" The rate of conversion of NDT to endoxifen by hCYP2D6 mouse liver microsomes (MLMs) in vitro was similar to that of the most active members of a panel of 13 individual human liver microsomes"><entity charOffset="27-35" id="DDI-PubMed.27756789.s6.e0" text="NDT" /></sentence><sentence text=" Coincubation with quinidine, a CYP2D6 inhibitor, ablated endoxifen generation by hCYP2D6 MLMs"><entity charOffset="19-28" id="DDI-PubMed.27756789.s7.e0" text="quinidine" /></sentence><sentence text=" The NDT-hydroxylation activity of wild-type MLMs was 7"><entity charOffset="5-13" id="DDI-PubMed.27756789.s8.e0" text="NDT" /></sentence><sentence text="4 times higher than that of hCYP2D6, whereas MLMs from Cyp2d knockout animals were inactive" /><sentence text=" Hydroxylation of NDT correlated with that of bufuralol, a CYP2D6 probe substrate, in the human liver microsome panel"><entity charOffset="46-55" id="DDI-PubMed.27756789.s10.e0" text="bufuralol" /><entity charOffset="18-26" id="DDI-PubMed.27756789.s10.e1" text="NDT" /><pair ddi="false" e1="DDI-PubMed.27756789.s10.e1" e2="DDI-PubMed.27756789.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27756789.s10.e1" e2="DDI-PubMed.27756789.s10.e0" /></sentence><sentence text=" In vitro, ADs of the selective serotonin reuptake inhibitor class were, by an order of magnitude, more potent inhibitors of NDT hydroxylation by hCYP2D6 MLMs than were compounds of the tricyclic class"><entity charOffset="32-41" id="DDI-PubMed.27756789.s11.e0" text="serotonin" /><entity charOffset="125-133" id="DDI-PubMed.27756789.s11.e1" text="NDT" /><pair ddi="false" e1="DDI-PubMed.27756789.s11.e0" e2="DDI-PubMed.27756789.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27756789.s11.e0" e2="DDI-PubMed.27756789.s11.e1" /></sentence><sentence text=" At a clinically relevant dose, paroxetine pretreatment inhibited the generation of endoxifen from NDT in hCYP2D6 mice in vivo"><entity charOffset="32-42" id="DDI-PubMed.27756789.s12.e0" text="paroxetine" /><entity charOffset="99-108" id="DDI-PubMed.27756789.s12.e1" text="NDT" /><pair ddi="false" e1="DDI-PubMed.27756789.s12.e0" e2="DDI-PubMed.27756789.s12.e0" /><pair ddi="false" e1="DDI-PubMed.27756789.s12.e0" e2="DDI-PubMed.27756789.s12.e1" /></sentence><sentence text=" These data demonstrate the potential of ADs to affect endoxifen generation and, thereby, the outcome of tamoxifen therapy"><entity charOffset="105-114" id="DDI-PubMed.27756789.s13.e0" text="tamoxifen" /></sentence><sentence text="" /></document>